

Special Issue

Amorphous Drug Formulations: Progress, Challenges and Perspectives

Message from the Guest Editor

The extensive academic research on amorphous drug formulations can be estimated by searching SCOPUS for two search terms, (amorphous) AND (drug). More than 3000 references were found for a 10-year period, and almost 2000 since 2017. Two main factors in increasing research in this area originate from (i) the poor solubility and bioavailability of newer APIs in the crystalline state, and (ii) the bioprotective effect of amorphous solids immobilizing labile therapeutic proteins. Physical instability remains a key problem of amorphous pharmaceuticals and biopharmaceuticals, and their vulnerability to various stresses during preparation, manufacturing processes or storage limits their therapeutic use. This Special Issue aims to focus on new strategies to make the use of amorphous drugs more common, combining advances in new formulations and methods for preparing formulations, supported by fundamental research on the amorphous solid-state. Original research articles and review articles dealing with all aspects of amorphous drug formulations from the design of new types of formulations to the evolution in the amorphizing and manufacturing processes are welcome.

Guest Editor

Prof. Dr. Alain Hedoux

CNRS, INRAE, Centrale Lille, UMR 8207, UMET – Unité Matériaux et Transformations, Université de Lille, F-59000 Lille, France

Deadline for manuscript submissions

closed (30 June 2023)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/126195

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy,
Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).